{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:29:25Z","timestamp":1786980565097,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,2,12]],"date-time":"2018-02-12T00:00:00Z","timestamp":1518393600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Natural Science Foundation of China Research, China","award":["No.21172043"],"award-info":[{"award-number":["No.21172043"]}]},{"name":"National Natural Science Foundation of China Research, China","award":["No.21441010"],"award-info":[{"award-number":["No.21441010"]}]},{"name":"Natural Science Foundation of Minhang District, Shanghai","award":["2014MHZ080"],"award-info":[{"award-number":["2014MHZ080"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s10147-018-1240-4","type":"journal-article","created":{"date-parts":[[2018,2,12]],"date-time":"2018-02-12T05:06:34Z","timestamp":1518411994000},"page":"458-465","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A phase II trial of concurrent chemoradiotherapy with weekly paclitaxel and carboplatin in advanced oesophageal carcinoma"],"prefix":"10.1007","volume":"23","author":[{"given":"Yi","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-hai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-hua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-ying","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ta-shan","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-ting","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harun","family":"Badakhshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuai-Le","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,12]]},"reference":[{"issue":"1","key":"1240_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1):7\u201330","journal-title":"CA Cancer J Clin"},{"key":"1240_CR2","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S0140-6736(12)60643-6","volume":"381","author":"A Pennathur","year":"2013","unstructured":"Pennathur A, Gibson MK, Jobe BA et al (2013) Oesophageal carcinoma. Lancet 381:400\u2013412","journal-title":"Lancet"},{"key":"1240_CR3","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1001\/jama.281.17.1623","volume":"281","author":"JS Cooper","year":"1999","unstructured":"Cooper JS, Guo MD, Herskovic A et al (1999) Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 281:1623\u20131627","journal-title":"JAMA"},{"issue":"1","key":"1240_CR4","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1200\/JCO.1997.15.1.277","volume":"15","author":"M al-Sarraf","year":"1997","unstructured":"al-Sarraf M, Martz K, Herskovic A et al (1997) Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 15(1):277\u2013284","journal-title":"J Clin Oncol"},{"key":"1240_CR5","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1093\/jnci\/86.14.1086","volume":"86","author":"JA Ajani","year":"1994","unstructured":"Ajani JA, Ilson DH, Daugherty K et al (1994) Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 86:1086\u20131091","journal-title":"J Natl Cancer Inst"},{"key":"1240_CR6","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.1002\/1097-0142(19930601)71:11<3774::AID-CNCR2820711147>3.0.CO;2-0","volume":"71","author":"H Choy","year":"1993","unstructured":"Choy H, Rodriguez FF, Koester S et al (1993) Investigation of taxol as a potential radiation sensitizer. Cancer 71:3774\u20133778","journal-title":"Cancer"},{"key":"1240_CR7","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1200\/JCO.1998.16.10.3316","volume":"16","author":"H Choy","year":"1998","unstructured":"Choy H, Akerley W, Safran H et al (1998) Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol 16:3316\u20133322","journal-title":"J Clin Oncol"},{"key":"1240_CR8","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S0360-3016(00)00420-X","volume":"47","author":"H Choy","year":"2000","unstructured":"Choy H, Devore RF, Hande KR et al (2000) A phase II study of paclitaxel, carboplatin, and hyper fractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study). Int J Radiat Oncol Bio Phys 47:931\u2013937","journal-title":"Int J Radiat Oncol Bio Phys"},{"issue":"2","key":"1240_CR9","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1200\/JCO.2001.19.2.442","volume":"19","author":"D Lau","year":"2001","unstructured":"Lau D, Leigh B, Gandara D et al (2001) Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin\/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial. J Clin Oncol 19(2):442\u2013447","journal-title":"J Clin Oncol"},{"issue":"10","key":"1240_CR10","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/sj.bjc.6603134","volume":"94","author":"E Meerten van","year":"2006","unstructured":"van Meerten E, Muller K, Tilanus HW et al (2006) Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study. Br J Cancer 94(10):1389\u20131394","journal-title":"Br J Cancer"},{"issue":"22","key":"1240_CR11","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","volume":"366","author":"P Hagen van","year":"2012","unstructured":"van Hagen P, Hulshof MC, van Lanschot JJ et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366(22):2074\u20132084","journal-title":"N Engl J Med"},{"issue":"24","key":"1240_CR12","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1056\/NEJM199206113262403","volume":"326","author":"A Herskovic","year":"1992","unstructured":"Herskovic A, Martz K, al-Sarraf M et al (1992) Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326(24):1593\u20131598","journal-title":"N Engl J Med"},{"key":"1240_CR13","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1200\/JCO.2002.20.5.1167","volume":"20","author":"BD Minsky","year":"2002","unstructured":"Minsky BD, Pajak TF, Ginsberg RJ et al (2002) INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 20:1167\u20131174","journal-title":"J Clin Oncol"},{"key":"1240_CR14","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1200\/JCO.2000.18.10.2032","volume":"18","author":"DJ Adelstein","year":"2000","unstructured":"Adelstein DJ, Rice TW, Rybicki LA et al (2000) Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. J Clin Oncol 18:2032\u20132039","journal-title":"J Clin Oncol"},{"key":"1240_CR15","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.ijrobp.2015.12.009","volume":"94","author":"LR Kleinberg","year":"2016","unstructured":"Kleinberg LR, Catalano PJ, Forastiere AA et al (2016) Eastern Cooperative Oncology Group and American College Of Radiology Imaging Network randomized phase 2 trial of neoadjuvant preoperative paclitaxel\/cisplatin\/radiation therapy (RT) or irinotecan\/cisplatin\/RT in esophageal adenocarcinoma: long-term outcome and implications for trial design. Int J Radiat Oncol Biol Phys 94:738\u2013746","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1240_CR16","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.1200\/JCO.2008.16.6918","volume":"26","author":"JA Ajani","year":"2008","unstructured":"Ajani JA, Winter K, Komaki R et al (2008) Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol 26:4551\u20134556","journal-title":"J Clin Oncol"},{"issue":"4","key":"1240_CR17","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/COC.0000000000000069","volume":"39","author":"H Tang","year":"2016","unstructured":"Tang H, Ma H, An SM et al (2016) A phase II study of concurrent chemoradiotherapy with paclitaxel and cisplatin for inoperable esophageal squamous cell carcinoma. Am J Clin Oncol 39(4):350\u2013354","journal-title":"Am J Clin Oncol"},{"issue":"9","key":"1240_CR18","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","volume":"16","author":"J Shapiro","year":"2015","unstructured":"Shapiro J, van Lanschot JJB, Hulshof MCCM et al (2015) Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 16(9):1090\u20131098","journal-title":"Lancet Oncol"},{"key":"1240_CR19","doi-asserted-by":"publisher","first-page":"e14508","DOI":"10.1200\/jco.2010.28.15_suppl.e14508","volume":"28","author":"EV Marten","year":"2010","unstructured":"Marten EV, van Rij C, Tesselaar ME et al (2010) Definitive concurrent chemoradiation (CRT) with weekly paclitaxel and carboplatin for patients (pts) with irresectabe esophageal cancer: a phase II study. J Clin Oncol 28:e14508","journal-title":"J Clin Oncol"},{"key":"1240_CR20","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1093\/annonc\/mdt589","volume":"25","author":"J Honing","year":"2014","unstructured":"Honing J, Smit JK, Muijs CT et al (2014) A comparison of carboplation and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 25:638\u2013643","journal-title":"Ann Oncol"},{"key":"1240_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/dote\/dow033","volume":"30","author":"MA Ruler van","year":"2017","unstructured":"van Ruler MA, Peters FP, Slingerland M et al (2017) Clinical outcomes of definitive chemoradiotherapy using carboplatin and paclitaxel in esophageal cancer. Dis Esophagus 30:1\u20139","journal-title":"Dis Esophagus"},{"issue":"3","key":"1240_CR22","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00280-014-2659-6","volume":"75","author":"T Miyazaki","year":"2015","unstructured":"Miyazaki T, Sohda M, Tanaka N et al (2015) Phase I\/II study of docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy in patients with advanced esophageal cancer. Cancer Chemother Pharmacol 75(3):449\u2013455","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"1240_CR23","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.ijrobp.2014.03.030","volume":"89","author":"K Higuchi","year":"2014","unstructured":"Higuchi K, Komori S, Tanabe S et al (2014) Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2). Int J Radiat Oncol Biol Phys 89(4):872\u2013879","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1240_CR24","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S1470-2045(13)70136-0","volume":"14","author":"T Crosby","year":"2013","unstructured":"Crosby T, Hurt CN, Falk S et al (2013) Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2\/3 randomised trial. Lancet Oncol 14:627\u2013637","journal-title":"Lancet Oncol"},{"issue":"5","key":"1240_CR25","first-page":"316","volume":"6","author":"DH Ilson","year":"2000","unstructured":"Ilson DH, Forastiere A, Arquette M et al (2000) A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J 6(5):316\u2013323","journal-title":"Cancer J"},{"key":"1240_CR26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13014-017-0785-0","volume":"12","author":"Y Xia","year":"2017","unstructured":"Xia Y, Li YH, Chen Y et al (2017) A phase II study of concurrent chemoradiotherapy combined with a weekly paclitaxel and 5-fluorouracil regimen to treat patients with advanced esophageal carcinoma. Radiat Oncol 12:47","journal-title":"Radiat Oncol"},{"key":"1240_CR27","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/S1556-0864(15)31576-8","volume":"1","author":"S Wang","year":"2006","unstructured":"Wang S, Liao Z, Chen Y et al (2006) Esophageal cancer located at the neck and upper thorax treated with concurrent chemoradiation: a single-institution experience. J Thorac Oncol 1:252\u2013259","journal-title":"J Thorac Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-018-1240-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-018-1240-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-018-1240-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,11]],"date-time":"2019-02-11T19:55:13Z","timestamp":1549914913000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-018-1240-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,12]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["1240"],"URL":"https:\/\/doi.org\/10.1007\/s10147-018-1240-4","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,12]]},"assertion":[{"value":"16 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}